APA (7th ed.) Citation

Rahalkar, H., Rahalkar, H., Cetintas, H. C., & Salek, S. (2018). Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Rahalkar, Hasumati, Hasumati Rahalkar, Hacer Coskun Cetintas, and Sam Salek. Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines. Frontiers Media S.A, 2018.

MLA (9th ed.) Citation

Rahalkar, Hasumati, et al. Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines. Frontiers Media S.A, 2018.